Mylan PE Ratio 2006-2018 | MYL

Current and historical p/e ratio for Mylan (MYL) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Mylan PE ratio as of October 19, 2018 is 7.06.
Mylan PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-10-19 32.21 37.45
2018-06-30 36.14 $0.86 42.02
2018-03-31 41.17 $1.34 30.72
2017-12-31 42.31 $1.29 32.80
2017-09-30 31.37 $1.61 19.48
2017-06-30 38.82 $1.22 31.82
2017-03-31 38.99 $1.00 38.99
2016-12-31 38.15 $0.91 41.92
2016-09-30 38.12 $0.51 74.75
2016-06-30 43.24 $1.57 27.54
2016-03-31 46.35 $1.56 29.71
2015-12-31 54.07 $1.66 32.57
2015-09-30 40.27 $1.75 23.01
2015-06-30 67.86 $2.18 31.13
2015-03-31 59.35 $2.18 27.22
2014-12-31 56.37 $2.34 24.09
2014-09-30 45.49 $2.32 19.61
2014-06-30 51.56 $1.46 35.32
2014-03-31 48.83 $1.60 30.52
2013-12-31 43.40 $1.58 27.47
2013-09-30 38.17 $1.52 25.11
2013-06-30 31.03 $1.63 19.04
2013-03-31 28.96 $1.50 19.30
2012-12-31 27.45 $1.53 17.94
2012-09-30 24.37 $1.44 16.92
2012-06-30 21.37 $1.29 16.57
2012-03-31 23.45 $1.29 18.18
2011-12-31 21.46 $1.22 17.59
2011-09-30 16.99 $0.93 18.27
2011-06-30 24.67 $0.90 27.41
2011-03-31 22.66 $0.73 31.04
2010-12-31 21.13 $0.70 30.19
2010-09-30 18.81 $0.70 26.87
2010-06-30 17.04 $0.24 71.00
2010-03-31 22.71 $0.27 84.11
2009-12-31 18.43 $0.23 80.13
2009-09-30 16.01 $0.09 177.89
2009-06-30 13.05 $0.67 19.48
2009-03-31 13.41 $0.45 29.80
2008-12-31 9.89 $-1.17 0.00
2008-09-30 11.42 $-6.08 0.00
2008-06-30 12.07 $-5.93 0.00
2008-03-31 11.60 $-5.58 0.00
2007-12-31 14.06 $-4.43 0.00
2007-09-30 15.96 $1.24 12.87
2007-06-30 18.19 $1.00 18.19
2007-03-31 21.07 $1.03 20.46
2006-12-31 19.84 $1.34 14.81
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $16.606B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $64.335B 11.04
Teva Pharmaceutical Industries (TEVA) Israel $21.792B 6.09
Bausch Health Cos (BHC) Canada $8.483B 6.32
Dr Reddy's Laboratories (RDY) India $5.756B 25.71
Supernus Pharmaceuticals (SUPN) United States $2.517B 26.93
Mallinckrodt Public (MNK) United Kingdom $2.287B 3.89
Akorn (AKRX) United States $0.882B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.857B 123.53
Homology Medicines (FIXX) United States $0.747B 0.00
CymaBay Therapeutics (CBAY) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.594B 0.00
Voyager Therapeutics (VYGR) United States $0.498B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.485B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.482B 0.00
Corium (CORI) United States $0.454B 0.00
Teligent (TLGT) United States $0.185B 0.00
Sol-Gel Technologies (SLGL) Israel $0.125B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.120B 0.00
Aevi Genomic Medicine (GNMX) United States $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
China Pharma Holdings (CPHI) China $0.019B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00